| Previous Close | 1.6000 |
| Open | 1.6100 |
| Bid | 1.4700 x 0 |
| Ask | 1.5000 x 0 |
| Day's Range | 1.4700 - 1.6400 |
| 52 Week Range | 1.2100 - 2.9600 |
| Volume | 63,835 |
| Avg. Volume | 28,155 |
| Market Cap | 56.269M |
| Beta (5Y Monthly) | 2.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3480 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
NervGen Pharma Receives Ethics Approval to Initiate Phase 1 Clinical Trial for NVG-291
Remains on Track to Dose First Subjects in Q2 2021 Vancouver, British Columbia--(Newsfile Corp. - April 14, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, has received approval and guidance from the Bellberry Human Research Ethics Committee ("HREC") in Australia on the design of a Phase 1 clinical trial for NVG-291, a specific ...
- Newsfile
NervGen Pharma Reports 2020 Year End Results
Vancouver, British Columbia--(Newsfile Corp. - April 8, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the year ended December 31, 2020.Paul Brennan, NervGen's President & CEO, stated, "We made substantial progress in the development of our lead program, NVG-291, towards clinical trials during 2020. We were ...
- Newsfile
NervGen Pharma Receives Orphan Designation from the European Medicines Agency for NVG-291 for the Treatment of Spinal Cord Injury
Vancouver, British Columbia--(Newsfile Corp. - March 8, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the European Medicines Agency ("EMA") has granted Orphan Designation for the treatment of spinal cord injury ("SCI") to NVG-291, a specific and selective protein tyrosine phosphatase sigma ("PTPσ") inhibitor. This new EMA designation provides NervGen ...
